Ann: Q3 2023 Business Update to Accompany Quarterly Results, page-71

Thanks for posting. So based on the information you've posted, the ProsAct Select interim data should be viewed in the context of longer overall survival rates even if initial PSA reduction doesn't look as favourable as Pluvicto? This being due to longer retention of radioactivity in the affected areas Vs Pluvicto?

With today's sp rout, I interpret this as the market has not received the interim results particularly well, perhaps expecting higher PSA reductions. But perhaps context is needed such as the information you've provided, and that Telix's therapy can still be positively differentiated with longer overall survival rates.

Well, it doesn't matter what I think because right now Telix is getting pummeled the likes of which I did not expect when I bought in not too long ago...